IRLAB Therapeutics has been granted a new composition of matter patent in the US for mesdopetam, potentially extending market exclusivity into the 2040s.
IRLAB Therapeutics receives positive feedback from EMA on Phase III program design for mesdopetam, aligning with previous FDA guidance for treating levodopa-induced dyskinesia in Parkinson's disease.
IRLAB Therapeutics achieved significant advancement in its Parkinson's disease pipeline, with positive Phase I data for IRL757 and receipt of a $2.5 million milestone payment in Q4 2024.
Roche initiates SKYLINE study, enrolling 1,250 participants aged 60-80 with early biological markers of Alzheimer's but no cognitive impairment, to evaluate gantenerumab's effectiveness in disease prevention.